학술논문
Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data
Document Type
article
Author
Anıl Tombak; Funda Pepedil Tanrıkulu; Salih Sertaç Durusoy; Hüseyin Derya Dinçyürek; Emin Kaya; Elif Gülsüm Ümit; İrfan Yavaşoğlu; Özgür Mehtap; Burak Deveci; Mehmet Ali Özcan; Hatice Terzi; Müfide Okay; Nilgün Sayınalp; Mehmet Yılmaz; Vahap Okan; Alperen Kızıklı; Ömer Özcan; Güven Çetin; Sinan Demircioğlu; İsmet Aydoğdu; Güray Saydam; Eren Arslan Davulcu; Gül İlhan; Mehmet Ali Uçar; Gülsüm Özet; Seval Akpınar; Burhan Turgut; İlhami Berber; Erdal Kurtoğlu; Mehmet Sönmez; Derya Selim Batur; Rahşan Yıldırım; Vildan Özkocaman; Ahmet Kürşad Güneş; Birsen Sahip; Şehmus Ertop; Olga Meltem Akay; Abdülkadir Baştürk; Mehmet Hilmi Doğu; Aydan Akdeniz; Ali Ünal; Ahmet Seyhanlı; Emel Gürkan; Demet Çekdemir; Burhan Ferhanoğlu
Source
Turkish Journal of Hematology, Vol 38, Iss 4, Pp 273-285 (2021)
Subject
Language
English
ISSN
1308-5263
Abstract
Objective: This study aimed to retrospectively evaluate the efficacy, safety, and survival outcome of single-agent ibrutinib therapy in chronic lymphocytic leukemia patients. Materials and Methods: A total of 136 patients (mean age +- standard deviation: 64.6+-10.3 years, 66.9% males) who had received at least one dose of ibrutinib were included in this retrospective multicenter, noninterventional hospital-registry study conducted at 33 centers across Turkey. Data on patient demographics, baseline characteristics, laboratory findings, and leukemia-cell cytogenetics were retrieved. Treatment response, survival outcome including overall survival (OS) and progression-free survival (PFS), and safety data were analyzed. Results: Overall, 36.7% of patients were categorized as Eastern Cooperative Oncology Group (ECOG) class 2-3, while 44.9% were in Rai stage 4. Fluorescence in situ hybridization revealed the presence of del(17p) in 39.8% of the patients. Patients received a median of 2.0 (range: 0-7) lines of pre-ibrutinib therapy. Median duration of therapy was 8.8 months (range: 0.4-58.0 months). The 1-year PFS and OS rates were 82.2% and 84.6%, respectively, while median PFS time was 30.0 (standard error, 95% confidence interval: 5.1, 20.0-40.0) months and median OS time was 37.9 (3.2, 31.5-44.2) months. Treatment response (complete or partial response), PFS time, and OS time were better with 0-2 lines versus 3-7 lines of prior therapy (p